Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
states has been reduced from 37 to 13 (2). Increased hepatitis A vaccination coverage, particularly through implementation of successful, nontraditional vaccination strategies among disproportionately affected populations (5), is needed to continue progress in halting current outbreaks and preventing similar outbreaks in the future.Health departments investigated HAV infections among persons who met the Council of State and Territorial Epidemiologists' hepatitis A case definition † using statespecific case investigation forms. Deidentified demographic, risk factor, and clinical outcome data were requested from all states reporting outbreaks for all outbreak-associated cases during August 1, 2016-December 31, 2020. Risk factors † https://ndc.services.cdc.gov/conditions/hepatitis-a-acute/
INSIDE
Abstract:Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects.
The U.S. Food and Drug Administration's accelerated approval of omacetaxine mepesuccinate for the treatment of chronic‐phase or accelerated‐phase chronic myeloid leukemia has been converted to full approval. Approved changes to the omacetaxine administration guidelines to allow home administration using syringes prepared by a health care professional will improve patient access to treatment by alleviating the need for daily visits to a medical facility during treatment, while also addressing concerns regarding the ability of patients or caregivers to accurately prepare and administer injections safely.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.